HUMA vs. JANX, EVO, OCUL, MESO, TVTX, BGM, GPCR, CVAC, CALT, and AMPH
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Janux Therapeutics (JANX), Evotec (EVO), Ocular Therapeutix (OCUL), Mesoblast (MESO), Travere Therapeutics (TVTX), BGM Group (BGM), Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.
Humacyte vs. Its Competitors
Janux Therapeutics (NASDAQ:JANX) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.
In the previous week, Humacyte had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 2 mentions for Humacyte and 1 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.30 beat Humacyte's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.
Janux Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500.
Janux Therapeutics has higher revenue and earnings than Humacyte. Janux Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Janux Therapeutics presently has a consensus price target of $95.25, suggesting a potential upside of 288.14%. Humacyte has a consensus price target of $11.71, suggesting a potential upside of 417.19%. Given Humacyte's higher possible upside, analysts plainly believe Humacyte is more favorable than Janux Therapeutics.
Humacyte's return on equity of 0.00% beat Janux Therapeutics' return on equity.
Summary
Janux Therapeutics beats Humacyte on 10 of the 16 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Humacyte Competitors List
Related Companies and Tools
This page (NASDAQ:HUMA) was last updated on 7/4/2025 by MarketBeat.com Staff
Free HUMA Stock Alerts